Jadeja’s 300th Test wicket helps India dismiss Bangladesh for 233
Bangladesh resumed their innings at 107-3 after rain and a wet outfield had washed out play on Saturday and Sunday.
Jadeja, playing in his 74th Test, started the match with 299 wickets and became the seventh Indian bowler to reach the 300-wicket mark. (Photo: Getty Images)
By EasternEyeSep 30, 2024
INDIA bowled out Bangladesh for 233 on day four of the rain-affected Test in Kanpur, with Ravindra Jadeja claiming his 300th Test wicket.
Jadeja reached the milestone when he dismissed Khaled Ahmed, caught and bowled, during the afternoon session. Mominul Haque remained unbeaten on 107.
Jadeja, playing in his 74th Test, started the match with 299 wickets and became the seventh Indian bowler to reach the 300-wicket mark. Anil Kumble tops the list with 619 Test wickets.
Jasprit Bumrah took three wickets, while Mohammed Siraj, Ravichandran Ashwin, and Akash Deep picked up two each.
Bangladesh resumed their innings at 107-3 after rain and a wet outfield had washed out play on Saturday and Sunday.
Mominul, starting the day on 40, brought up his 13th Test century before lunch, hitting a boundary off Ashwin. He removed his helmet and bowed to celebrate.
Bumrah made an early breakthrough, bowling Mushfiqur Rahim for 11 with a ball that pitched and nipped back to hit the off-stump.
Litton Das countered with three boundaries off Bumrah in one over but was dismissed for 13 when Rohit Sharma took a one-handed catch at mid-off off Siraj’s bowling.
Siraj followed up by catching Shakib Al Hasan off Ashwin’s bowling for nine, running back from mid-off to complete the catch.
Shakib, who announced his international retirement on Thursday, could be playing his last Test match.
Only 35 overs had been possible on the opening day before bad light stopped play shortly after lunch.
India leads the two-match series 1-0, having won the first Test in Chennai by 280 runs.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.